Dec 8 (Reuters) - Medical supplies giant Medline said on Monday it was targeting an up to $55.3 billion valuation in its hotly anticipated U.S. initial public offering that is expected to be 2025's biggest
IPO.
The Northfield, Illinois-based company is offering 179 million shares priced between $26 and $30 apiece.
With the Thanksgiving slowdown behind, the U.S. IPO market is poised for a burst of activity in the next fortnight as companies rush to seize the final 2025 window before the holiday lull kicks in.
Medline's blockbuster share sale is poised to be one of the year’s marquee listings, serving as a key gauge of investor sentiment as markets head into 2026.
Headwinds ranging from Liberation Day to the longest-ever U.S. government shutdown have weighed on the new listings market this year. Still, IPO activity in New York this year has hit the highest level since the 2021 boom.
Medline was founded in 1966 by brothers James and Jon Mills. It traces its roots to a garment manufacturer, which initially made butcher's aprons for the meatpacking industry starting in 1910.
Cornerstone investors have indicated their interest in buying up to $2.35 billion worth of shares from Medline's offering.
Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are the lead bookrunning managers for the offering.
Medline will list on the Nasdaq under the trading symbol "MDLN".
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Alan Barona and Maju Samuel)
